Methods and compositions involving miRNA and miRNA inhibitor molecules
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12N-015/11
C12Q-001/68
C12N-015/113
A61K-009/127
A61K-031/7088
출원번호
US-0459074
(2014-08-13)
등록번호
US-9068219
(2015-06-30)
발명자
/ 주소
Brown, David
Ford, Lance
Cheng, Angie
Jarvis, Rich
Byrom, Mike
Ovcharenko, Dmitriy
Devroe, Eric
Kelnar, Kevin
출원인 / 주소
Asuragen, Inc.
대리인 / 주소
Nutter McClennen & Fish LLP
인용정보
피인용 횟수 :
1인용 특허 :
94
초록▼
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therape
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
대표청구항▼
1. A method comprising introducing into a cancer cell an effective amount of a synthetic miR-215 molecule comprising a miR-215 active strand and a separate passenger strand that is at least 60% complementary to the active strand. 2. The method of claim 1, wherein the synthetic miR-215 molecule is no
1. A method comprising introducing into a cancer cell an effective amount of a synthetic miR-215 molecule comprising a miR-215 active strand and a separate passenger strand that is at least 60% complementary to the active strand. 2. The method of claim 1, wherein the synthetic miR-215 molecule is non-naturally occurring and markedly different in sequence from naturally occurring miR-215. 3. The method of claim 1, wherein the synthetic miR-215 molecule is non-naturally occurring and markedly different in chemical structure from naturally occurring miR-215. 4. The method of claim 1, wherein the sequence of the synthetic miR-215 molecule is not naturally occurring. 5. The method of claim 1, wherein at least one nucleobase of the synthetic miR-215 molecule is chemically modified. 6. The method of claim 1, wherein the complementary strand is not naturally occurring. 7. The method of claim 1, wherein the complementary strand comprises a chemical modification that improve uptake of the synthetic oligonucleotide. 8. The method of claim 1, wherein the complementary strand comprises a chemical modification that enhance activity of the synthetic oligonucleotide. 9. The method of claim 1, wherein the complementary strand comprises a chemical modification that enhance stability of the synthetic oligonucleotide. 10. The method of claim 1, wherein the complementary strand comprises a chemical modification that inhibit uptake of the complementary strand. 11. The method of claim 1, wherein the complementary strand comprises a chemical modification that inhibits activity of the complementary strand. 12. The method of claim 1, wherein the complementary strand comprise one or more nucleobases that are non-complementary with the synthetic oligonucleotide. 13. The method of claim 1, wherein the synthetic miR-215 molecule is in a pharmaceutical composition. 14. The method of claim 13, wherein the pharmaceutical composition is a sterile aqueous solution. 15. The method of claim 1, wherein the synthetic miR-215 molecule is in a liposomal pharmaceutical delivery system. 16. The method of claim 13, wherein the pharmaceutical composition comprises an antibacterial or antifungal agent. 17. The method of claim 13, wherein the pharmaceutical composition comprises about 2% to about 75% by weight (w/w) of the synthetic miR-215 molecule. 18. The method of claim 13, wherein the synthetic miR-215 molecule is at least about 95, 96, 97, 98, 99, or 100% pure. 19. The method of claim 13, wherein the pharmaceutical composition is aliquoted in a vial, test tube, flask, bottle, syringe, or container. 20. The method of claim 1, wherein introducing into the cell the effective amount of the synthetic miR-215 molecule comprises administering the synthetic miR-215 molecule to a subject comprising the cell. 21. The method of claim 20, wherein the effective amount is a dose of about 5 mg/kg body weight to about 100 mg/kg body weight of the subject. 22. The method of claim 20, wherein the pharmaceutical composition is administered to the subject topically, intravenously, by injection, transdermally, transmucosally, by inhalation, orally, or pulmonarily. 23. The method of claim 20, wherein the subject has a cancer. 24. The method of claim 20, wherein the synthetic miR-215 molecule induces apoptosis in the cell in the subject. 25. The method of claim 1, wherein the synthetic miR-215 molecule induces apoptosis in the cell. 26. The method of claim 1, wherein the synthetic miR-215 molecule comprises a sequence that is at least 80% identical to residues 27-47 of SEQ ID NO:162. 27. The method of claim 1, wherein the synthetic miR-215 molecule comprises a sequence that is identical to residues 27-47 of SEQ ID NO:162. 28. The method of claim 1, wherein the pharmaceutical composition comprises about 25% to about 60% by weight (w/w) of the synthetic miR-215 molecule. 29. The method of claim 1, wherein the synthetic miR-215 molecule is in a dose of about 5 mg/kg body weight to about 500 mg/kg body weight. 30. The method of claim 1, wherein the cancer cell is a breast cancer cell. 31. The method of claim 1, wherein the cancer cell is a cervical cancer cell. 32. The method of claim 1, wherein the cancer cell is a colon cancer cell. 33. The method of claim 1, wherein the cancer cell is a skin cancer cell.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (94)
Lee Linda ; Benson Scott C. ; Rosenblum Barnett B. ; Spurgeon Sandra L., 4, 7-Dichlororhodamine dyes.
Menchen Steven M. (Fremont CA) Lee Linda G. (Palo Alto CA) Connell Charles R. (Redwood City CA) Hershey N. Davis (San Carlos CA) Chakerian Vergine (San Mateo CA) Woo Sam (Redwood City CA) Fung Steven, 4,7-dichlorofluorescein dyes as molecular probes.
Milburn Susan C. (Austin TX) Goldrick Marianna (Pflugerville TX) Winkler Matthew (Austin TX), Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reac.
Milburn, Susan C.; Goldrick, Marianna; Winkler, Matthew, Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions.
Milburn, Susan; Goldrick, Marianna; Winkler, Matthew, Compositions and methods for increasing the yields of the in vitro RNA transcription and other polynucleotide synthetic reactions.
Von Wronski,Mathew A.; Marinelli,Edmund R.; Nunn,Adrian D.; Pillai,Radhakrishna; Ramalingam,Kondareddiar; Tweedle,Michael F.; Linder,Karen; Nanjappan,Palaniappa; Raju,Natarajan, Compounds for targeting endothelial cells, compositions containing the same and methods for their use.
Sobol Robert E. (LaJolla CA) Green Mark R. (San Diego CA) Kawasaki Ernest S. (Richmond CA), Detection of carcinoma metastases by nucleic acid amplification.
Maruyama,Toshiaki; Frederickson,Shana; Bowdish,Katherine S.; Renshaw,Mark; Lin,Ying Chi, Engineered templates and their use in single primer amplification.
Lockhart David J. ; Brown Eugene L. ; Wong Gordon G. ; Chee Mark S. ; Gingeras Thomas R., Expression monitoring by hybridization to high density oligonucleotide arrays.
Sedlacek Hans-Harald,DEX ; Bosslet Klaus,DEX ; Muller Rolf,DEX, Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound.
Jonathan Marc Rothberg ; Michael W. Deem ; John W. Simpson, Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing.
Rothberg Jonathan Marc ; Deem Michael W. ; Simpson John W., Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing.
Livak Kenneth J. (San Jose CA) Flood Susan J. A. (Fremont CA) Marmaro Jeffrey (Foster City CA), Method for detecting nucleic acid amplification using self-quenching fluorescence probe.
Lloyd,John Scott; Weston,Anthony; Cardy,Donald Leonard Nicholas, Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
van Gemen, Bob; Timmermans, Eveline Catherina A. C.; de Ronde, Anthonij; Dobbelaer, Irene Johanna M., Method of determining therapeutic activity and/or possible side-effects of a medicament.
Dai,Hongyue; He,Yudong; Linsley,Peter S.; Mao,Mao; Roberts,Christopher J.; Van't Veer,Laura Johanna; Van de Vijver,Marc J.; Bernards,Rene; Hart,A. A. M., Methods of assigning treatment to breast cancer patients.
Huang,Mingxian; Wu,Lei; Wang,Xiaobo; Xu,Junquan; Tao,Guo Liang; Rothwarf,David M., Microdevices having a preferential axis of magnetization and uses thereof.
David J. Lockhart ; Mark Chee ; Kevin Gunderson ; Lai Chaoqiang ; Lisa Wodicka ; Maureen T. Cronin ; Danny Lee ; Huu M. Tran ; Hajime Matsuzaki, Nucleic acid analysis techniques.
Duck Peter (Ottawa CAX) Bender Robert (Ottawa CAX) Crosby William (Saskatoon CAX) Robertson John G. (L\Ange Gardien CAX), Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences.
Keys, Daniel A.; Farooqui, Firdous; Reddy, M. Parameswara, Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer.
Van Gelder Russell N. (2200 Divot Dr. Crystal Lake MD 63131) Von Zastrow Mark E. (11570 Buena Vista Dr. Los Altos CA 94022) Barchas Jack D. (1900 Rittenhouse Sq. #18A Philadelphia PA 19103) Eberwine , Process for amplifying a target polynucleotide sequence using a single primer-promoter complex.
Bergot B. John (Redwood City CA) Chakerian Vergine (San Mateo CA) Connell Charles R. (Redwood City CA) Eadie J. Scott (Indianapolis IN) Fung Steven (Palo Alto CA) Hershey N. Davis (San Carlos CA) Lee, Spectrally resolvable rhodamine dyes for nucleic acid sequence determination.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.